Pathos AI has launched a $400 million funding round and already raised nearly $283 million. The Chicago-based startup formed ...

Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report ...

AstraZeneca, Tempus and Pathos will develop an AI-driven foundational model to develop therapeutics in oncology.

Tempus AI (TEM) has seen a significant surge on Wednesday, with its stock climbing 14.62% in just one day. The significant boost in TEM stock ...

“Generative AI and the emergence of large multimodal models is the final catalyst needed to usher in precision medicine in ...

Tempus AI Inc (NASDAQ:TEM) shares closed up 14.5% following the announcement of expanded strategic partnerships with ...

Many of America’s wealthiest business leaders have lost millions — if not billions — of dollars in net worth since the start ...

Tempus stands to earn $200 million in data licensing and model development fees from the collaborations, the release said.

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ...

“Generative AI and the emergence of large multimodal models is the final catalyst needed to usher in precision medicine in oncology at scale,” said Eric Lefkofsky, Founder and CEO of Tempus. “Tempus ...

DEAR ERIC: My husband of 50 years passed away suddenly last year. We had just moved into a retirement community. I still hurt deeply but not all the time anymore. My neighbor is facing a similar ...

Dear Eric: My husband of 50 years passed away suddenly last year. We had just moved into a retirement community. I still hurt deeply but not all the time anymore. My neighbor is facing a similar ...